Larimar Therapeutics
LRMR
77 hedge funds and large institutions have $45.9M invested in Larimar Therapeutics in 2016 Q3 according to their latest regulatory filings, with 14 funds opening new positions, 23 increasing their positions, 20 reducing their positions, and 10 closing their positions.
40% more first-time investments, than exits
New positions opened: 14 | Existing positions closed: 10
15% more repeat investments, than reductions
Existing positions increased: 23 | Existing positions reduced: 20
5% more funds holding
Funds holding: 73 → 77 (+4)
55% less capital invested
Capital invested by funds: $103M → $45.9M (-$56.9M)
59% less call options, than puts
Call options by funds: $266K | Put options by funds: $655K
67% less funds holding in top 10
Funds holding in top 10: 3 → 1 (-2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RA
Royce & Associates
New York
|
+$1.91M |
| 2 |
PAM
Panagora Asset Management
Boston,
Massachusetts
|
+$902K |
| 3 |
Northern Trust
Chicago,
Illinois
|
+$823K |
| 4 |
Dimensional Fund Advisors
Austin,
Texas
|
+$745K |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$561K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DM
Deerfield Management
New York
|
-$18.3M |
| 2 |
FCM
Farallon Capital Management
San Francisco,
California
|
-$5.02M |
| 3 |
GIM
Granahan Investment Management
Waltham,
Massachusetts
|
-$3.17M |
| 4 |
Balyasny Asset Management
Chicago,
Illinois
|
-$973K |
| 5 |
Alyeska Investment Group
Chicago,
Illinois
|
-$946K |
LRMR Hedge Fund Activity: Q3 2016 in Review
77 of the 3,759 institutional investors tracked by Wall St. Rank reported a position in Larimar Therapeutics (LRMR) for Q3 2016, worth a combined $45.9M — down 55% from $103M a quarter earlier.
Buyers outnumbered sellers: 14 funds opened new LRMR positions and 10 closed out — a net gain of 4 holders — while 23 added to existing stakes and 20 trimmed.
The largest buyer was Royce & Associates, opening a new position worth an estimated $1.91M. The largest seller was Deerfield Management, exiting entirely with an estimated $18.3M sold.
- 77 institutional investors held Larimar Therapeutics (LRMR) as of Q3 2016, up from 73 in Q2 2016.
- Funds reported $45.9M of Larimar Therapeutics stock for Q3 2016, down 55% quarter-over-quarter.
- 14 funds opened new Larimar Therapeutics positions in Q3 2016 and 10 closed out, a net change of +4 holders.
- The largest Larimar Therapeutics buyer in Q3 2016 was Royce & Associates, an estimated $1.91M added.
- The largest Larimar Therapeutics seller in Q3 2016 was Deerfield Management, an estimated $18.3M sold.
Based on aggregated 13F filings for Q3 2016.